Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON (JNJ)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Johnson & Johnson : Reports on Pharmaceutical Research Findings from Johnson & Johnson Provide New Insights (Importance of in vitro dissolution conditions for the in...

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 05:58pm CET

Reports on Pharmaceutical Research Findings from Johnson & Johnson Provide New Insights (Importance of in vitro dissolution conditions for the in vivo predictability of an amorphous solid dispersion containing a pH-sensitive carrier)

By a News Reporter-Staff News Editor at Drug Week -- Investigators publish new report on Drugs and Therapies - Pharmaceutical Research. According to news reporting originating from Beerse, Belgium, by NewsRx correspondents, research stated, "The present study investigated the influence of in vitro dissolution conditions on the in vivo predictability of an amorphous solid dispersion of celecoxib (CCX) in the pH-sensitive polymer Eudragit ® S 100. Different doses of a 25:75 w/w% CCX: Eudragit ® S 100 amorphous solid dispersion (CCX:EUD) were investigated."

Our news editors obtained a quote from the research from Johnson & Johnson, "During in vitro dissolution a significant effect of the pH of the dissolution media on the release of CCX was observed. In fasted state simulated intestinal fluid (FaSSIF) pH 6.5, the release of CCX from the amorphous solid dispersion was comparable to that of crystalline CCX and lower than that of amorphous CCX whereas in FaSSIF pH 7.4, the release was significantly increased compared to both crystalline and amorphous CCX. With a 3-fold increase in the exposure of CCX: EUD compared to crystaline CCX. The in vivo data also suggested that Eudragit ® S 100 was suitable as a carrier in amorphous solid dispersions of CCX. In vitro-in vivo correlation demonstrated that the in vitro data obtained in FaSSIF pH 7.4 was more predictive for the in vivo performance than that obtained in FaSSIF pH 6.5."

According to the news editors, the research concluded: "Consequently, the findings of this study underline that when predicting the in vivo performance of amorphous solid dispersions with pH-sensitive polymers, it is imperative that the in vitro dissolution conditions are carefully considered."

For more information on this research see: Importance of in vitro dissolution conditions for the in vivo predictability of an amorphous solid dispersion containing a pH-sensitive carrier. International Journal of Pharmaceutics, 2017;531(1):324-331. International Journal of Pharmaceutics can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; International Journal of Pharmaceutics - www.journals.elsevier.com/international-journal-of-pharmaceutics/)

The news editors report that additional information may be obtained by contacting R. Holm, Johnson & Johnson, Drug Prod Dev, Janssen Res & Dev, BE-2340 Beerse, Belgium. Additional authors for this research include M.M. Knopp, F. Khan, N. Chourak, T. Rades and J. Wendelboe (see also Drugs and Therapies - Pharmaceutical Research).

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1016/j.ijpharm.2017.08.078. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Keywords for this news article include: Beerse, Belgium, Europe, Pharmaceutical Research, Drugs and Therapies, Johnson & Johnson.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
03:32p JOHNSON & JOHNSON : LSP closes second health economic fund at EUR 280M
02:34p JOHNSON & JOHNSON : DARZALEX® (daratumumab) Combination Regimen Significantly Im..
02:01p JOHNSON & JOHNSON : Motus GI Appoints Gary J. Pruden, Former Worldwide Chairman ..
01:54p JOHNSON & JOHNSON : Joins HIV Campaign
12:46p Sanofi investors hungry for drug progress and deal news
12:09a JOHNSON & JOHNSON : New Data for DARZALEX® (daratumumab) Presented at ASH 2017 S..
12/11 JOHNSON & JOHNSON : Sustained Benefit in Patients With Relapsed/Refractory Mantl..
12/11 JOHNSON & JOHNSON : How Johnson & Johnson is Helping Support Service Members Thr..
12/11 JOHNSON & JOHNSON : Wetherby Asset Management Holds Holding in Johnson & Johnson..
12/09 JOHNSON & JOHNSON : Sustained Benefit in Patients with Relapsed/Refractory Mantl..
More news
News from SeekingAlpha
10:48a MCDONALD'S : Dividend Increase For Income And Good Total Return
07:38a Positive Market In 2017 - Cramer's Mad Money (12/11/17)
12/11 Johnson & Johnson files U.S. marketing application for expanded label use of ..
12/11 Where To Invest To Benefit From The Corporate Tax Cut
12/10 BIOTECH IN 2018 : Will Repatriated Cash Fuel A Feeding Frenzy?
Financials ($)
Sales 2017 76 324 M
EBIT 2017 23 523 M
Net income 2017 16 391 M
Debt 2017 17 115 M
Yield 2017 2,37%
P/E ratio 2017 23,66
P/E ratio 2018 19,47
EV / Sales 2017 5,19x
EV / Sales 2018 4,79x
Capitalization 379 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 146 $
Spread / Average Target 3,2%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON21.53%379 175
NOVARTIS12.15%218 773
PFIZER9.30%215 837
ROCHE HOLDING LTD.3.40%209 423
MERCK AND COMPANY-6.96%153 659
AMGEN18.98%128 363